Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CAR macrophages with built-In CD47 blocker combat tumor antigen heterogeneity and activate T cells via cross-presentation

30 Apr 2025

Abstract excerpt

Macrophage-based cancer cellular therapy has gained substantial interest. However, the capability of engineered macrophages to target cancer heterogeneity and modulate adaptive immunity remains unclear. Here, exploiting the myeloid antibody-dependent cellular phagocytosis biology and phagocytosis checkpoint blockade, we report the enhanced synthetic phagocytosis receptor (eSPR) that integrate FcRγ-driven...

Topics

Join the communities discussing this publication.

CAR-T cell therapy research
Immune cells in cancer
Phagocytosis and Immune Regulation

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 40307254
DOI: 10.1038/s41467-025-59326-9

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CAR macrophages with built-In CD47 blocker combat tumor antigen heterogeneity and activate T cells via cross-presentationPMID 40307254Read ↗

Chimeric antigen receptors that trigger phagocytosisSemantic proximity Read ↗

CD47 predominates over CD24 as a macrophage immune checkpoint in cancerSemantic proximity Read ↗

Harnessing and Enhancing Macrophage Phagocytosis for Cancer Therapy.Semantic proximity Read ↗

CAR-MACROPHAGES ACTIVATE ANTI TUMOR T CELLS IN THE ABSENCE OF PHAGOCYTOSISSemantic proximity Read ↗

Engineered CAR-Macrophages as Adoptive Immunotherapies for Solid Tumors.Semantic proximity Read ↗

Manipulating macrophage polarization in cancer patients: From nanoparticles to human chimeric antigen receptor macrophages.Semantic proximity Read ↗

Targeting PD-L1 in solid cancer with myeloid cells expressing a CAR-like immune receptorSemantic proximity Read ↗

Breaking the immunosuppressive barrier: an armored CAR-M biotechnology with the original M1 phenotype dominance rescues antitumor immunity.Semantic proximity Read ↗

Inhibition of furin in CAR macrophages directs them toward a proinflammatory phenotype and enhances their antitumor activities.Semantic proximity Read ↗

An immune-stimulating antibody conjugate spatiotemporally targeting CD47 and TLR9 elicits macrophage-dependent tumor clearance and durable anti-cancer adaptive immunitySemantic proximity Read ↗

Organoid modeling of tumor-associated macrophages reveals phagocytosis checkpoint blockade-induced conversion to an immunosuppressive SPP1+ phenotypeSemantic proximity Read ↗

Cancer cell phagocytosis induces an anti-inflammatory gene regulatory program in macrophagesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.